Pascal Hammel
Université Paris-Saclay(FR)Délégation Ile-de-France Villejuif(FR)Assistance Publique – Hôpitaux de Paris(FR)Assistance Publique – Hôpitaux de Paris(FR)Laboratoire d'études sur les monothéismes(FR)Hôpital Paul-Brousse(FR)Hôpital Paul-Brousse(FR)
Publications by Year
Research Areas
Pancreatic and Hepatic Oncology Research, Neuroendocrine Tumor Research Advances, Cancer Genomics and Diagnostics, Pancreatitis Pathology and Treatment, Cholangiocarcinoma and Gallbladder Cancer Studies
Most-Cited Works
- → FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer(2018)2,781 cited
- → Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors(2011)2,525 cited
- → Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial(2017)1,902 cited
- → Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib(2016)1,049 cited
- → Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial(2005)954 cited
- → Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study